Aprea Therapeutics, Inc. Form 8-K Filing

Aprea Therapeutics, Inc. filed a Form 8-K on March 16, 2026, reporting its financial results for the fourth quarter and full year ended December 31, 2025, along with an operational update. The company announced early clinical proof-of-concept for its WEE1 inhibitor, APR-1051, with two partial responders in endometrial cancer patients. They also strengthened their clinical team with the appointment of Dr. Eugene Kennedy as Chief Medical Advisor and confirmed sufficient capital to support key milestones. Financial results showed a net loss of $2.5 million for Q4 2025 and $12.6 million for the full year 2025. The company ended 2025 with $14.6 million in cash and cash equivalents, with projections to meet operating expenses into the first quarter of 2027. Additionally, Aprea Therapeutics updated its corporate presentation, highlighting its pipeline and development strategies.